Antitrust scrutiny of healthcare markets is nothing new. The Biden Administration and first Trump Administration focused antitrust enforcement efforts across the healthcare and life sciences industries. The newly installed Trump Administration is poised to continue its focus on antitrust enforcement in healthcare markets. Beyond federal enforcers, state AGs are also likely to remain active in the healthcare space, particularly in “blue” states that might perceive federal antitrust enforcement as insufficient.
Originally published in the CPI Antitrust Chronicle - May 2025.
Please see full publication below for more information.
